Regular updates related to sourcing and the management of health products are available on this page. You can receive a notification every time a new update is published by using our really simple syndication (RSS) feed. See our RSS Feeds page for more information.
The Global Fund, Stop TB Partnership Global Drug Facility and Unitaid are inviting manufacturers of antiretroviral (HIV/AIDS), antihepatitis B and C, antituberculosis and antimalarial medicines to submit an expression of interest to have their products evaluated by the Expert Review Panel for Pharmaceutical Products.
The Global Fund is working with partners to rapidly and equitably support access to COVID-19 health products and diagnostics for low- and middle-income countries by following the World Health Organization’s allocation model.
Following the World Health Organization’s interim guidance on antigen-detection in the diagnosis of COVID-19 from 11 September, the Global Fund anticipates being able to support countries in accessing high-performing antigen-detecting rapid diagnostic tests (Ag-RDTs) as soon the specific products receive WHO quality assurance approval, which is expected very soon.